An observational study in Coronary Artery Disease and Percutaneous Coronary Intervention, sponsored by University of Florida. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by University of Florida · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Coronary Artery Disease by University of Florida — 6 open to participants now, 8 under way, none of them phase 3. Coronary Artery Disease · University of Florida.
Among the 40 studies in Coronary Artery Disease by University of Florida, this one is one of 2 that started in 2020, is one of 5 observational ones, and was the 34th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →6 of the 40 studies in Coronary Artery Disease by University of Florida are open now, in 1 country. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 18–75
University of Florida · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,643 is above the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 60 across the 35 interventional studies, 1,000 across the 5 observational. Of the 32 that completed or were terminated, 24 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Florida is the lead sponsor of 1,290 studies on the registry; 202 are open to participants now.
Of its 181 completed or terminated interventional studies of FDA-regulated products, 143 (79%) have results posted.
6 of the studies in Coronary Artery Disease by University of Florida that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05332262University of FloridaA Precision Medicine Approach to Identify Patients Undergoing Elective PCI at Risk of Peri-PCI Myocardial Infarction | 2026-12 |
| NCT06691191University of FloridaSwitching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors | 2026-12-31 |
| NCT06228456University of FloridaEffects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention | 2026-12-31 |
| NCT06143709University of FloridaPrecision PCI Registry | 2027-06-30 |
| NCT07025148University of FloridaDual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2) | 2027-08-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 40 studies in Coronary Artery Disease by University of Florida, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The feasibility and clinical benefit of using a patient's genotype to guide antiplatelet therapy prescribing has been demonstrated. However, a more precise understanding of who to genotype, what to include on a genetic testing panel, and how to change antiplatelet therapy based on genotype results and other patient-specific factors is needed to optimize the impact of genotype-guided antiplatelet therapy on patient outcomes.
The Precision PCI registry is a collaboration between the University of Florida, Gainesville and Jacksonville, USA, the University of North Carolina, Chapel Hill, USA, and University of Maryland, Baltimore, USA. This registry will include a diverse population of patients who undergo Percutaneous Coronary Intervention and clinical CYP2C19 genotyping, assess clinical outcomes over 12 months and collect DNA samples for additional genotyping, and conduct pharmacodynamic analysis of platelet function in a subset of patients.
Objectives of the study:
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) is the standard of care after percutaneous coronary intervention (PCI) to reduce the risk of atherothrombotic events. Prasugrel and ticagrelor are preferred over clopidogrel in patients with an acute coronary syndrome but are associated with greater bleeding risk. The cytochrome P450 (CYP)2C19 enzyme is essential for metabolism of clopidogrel (a prodrug) to its pharmacologically active form. Approximately 30% of the U.S. population carries a CYP2C19 loss-of-function (LOF) allele that reduces the bioactivation and effectiveness of clopidogrel, but not prasugrel or ticagrelor, after PCI.
Previous studies have demonstrated the feasibility and effectiveness of incorporating CYP2C19 genotyping into clinical care to guide DAPT, with prasugrel or ticagrelor prescribed in patients with a CYP2C19 LOF allele. However, the influence of key patient-specific factors on outcomes with genotype-guided DAPT (notably African ancestry, comorbidities that impact clopidogrel effectiveness, and genotypes beyond CYP2C19) has not been defined but is critical to understand in order to optimize the clinical impact of genotype-guided DAPT. Moreover, the impact on clinical outcomes of using CYP2C19 genotype to guide de-escalation from more potent agents (e.g., prasugrel or ticagrelor) to clopidogrel in patients without a LOF allele, which has become highly clinically relevant due to more frequent initial use of prasugrel or ticagrelor after acute coronary syndrome and PCI, has not been investigated in a diverse, real-world clinical setting.
The long-term goal of this line of research is to optimize a precision medicine DAPT strategy that improves outcomes after PCI. The investigators hypothesize that multiple clinical and genetic factors jointly contribute to the effectiveness and safety of CYP2C19 LOF allele-guided selection of DAPT after PCI in a real-world clinical setting. This hypothesis will be tested by conducting a multi-center, observational study of 1,500 patients with PCI and clinical CYP2C19 genetic testing.
Aim 1: Define the influence of African ancestry and other patient-specific factors on clinical outcomes with CYP2C19 genotype-guided DAPT after PCI in a real-world setting
Aim 2: Evaluate the safety and effectiveness of CYP2C19 genotype-guided de-escalation of DAPT following PCI in a real-world setting
Aim 3: Elucidate the effect(s) of genetic variants beyond CYP2C19 LOF alleles on platelet reactivity and clinical outcomes with clopidogrel after PCI
A total of 1500 patients will be enrolled. Their data will be added to an existing cohort of approximately 4500 patients to address these aims.
Baseline data from the PCI admission will include:
Follow-up Data:
Patient follow-up will occur at 1, 6, and 12 months after PCI or until DAPT discontinuation via telephone call and EHR review to assess for hospitalizations and medication changes.
Data Management:
Data will be stored electronically in a secured database that is only accessible to study investigators. Quality assurance procedures will include use of a data dictionary, data checks ensure compliance with predefined rules for data ranges and checks for missing data. Hospitalization records will be reviewed by independent cardiologists to verify atherothrombotic and bleeding events. Deaths will be assessed by query of the National Death Index (NDI) and North Carolina state death index.
The target patient population will be male or female adults (age 18 years), of any race or ethnicity, who undergo PCI and clinical CYP2C19 genotyping, and are treated with clopidogrel, prasugrel, or ticagrelor in addition to aspirin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who have undergone PCI and clinical CYP2C19 genotyping
Other: DNA sample collection
Patients will be asked to provide a blood or mouth wash sample for DNA extraction
Major atherothrombotic events
Composite of death, myocardial infarction, ischemic stroke, stent thrombosis, and revascularization for unstable angina
Time frame: 12 months
Net clinical benefit
Major atherothrombotic events or clinically significant bleeding
Time frame: 12 months
Major adverse cardiovascular events
Composite of cardiovascular death, myocardial infarction, ischemic stroke, and stent thrombosis
Time frame: 12 months
Clinically significant bleeding
Moderate or severe/life-threatening bleeding according to GUSTO criteria
Time frame: 12 months
All cause death
Death from any cause
Time frame: 12 months
Cardiovascular death
Death resulting from myocardial infarction, arrhythmia, heart failure, stroke, or other cardiovascular cause
Time frame: 12 months
Myocardial infarction
New ischemic symptoms and troponin elevation
Time frame: 12 months
Ischemic stroke
Acute neurologic deficit that lasts over 24 hours and affects the ability to perform daily activities with or without confirmation of imaging
Time frame: 12 months
Stent thrombosis
Definite or probable stent thrombosis defined according to the Academic Research Consortium
Time frame: 12 months
Unstable angina
Acute ischemic event with no evidence of myocardial infarction and angiographic evidence of new or worsening obstructive coronary disease, or intracoronary thrombus, believed to be responsible for the ischemic symptoms and requiring coronary revascularization
Time frame: 12 months
Plan to share: Yes — We will comply with the NIH Genomic Data Sharing Policy (https://gds.nih.gov/). Institutional Review Board approval and institutional certification will be obtained for the submission of the study data to open-access databases such as the database of Genotypes and Phenotypes (dbGaP). This will be done after all of the individual participant data is collected during the trial, and after deidentification.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: De-identified genomic and phenotype data to be made available by depositing these data in dbGaP as soon as possible but no later than within one year of the completion of the funded project period or upon acceptance of the data for publication.
Access criteria: Data will be available as controlled-access data through dbGaP, in which interested users must submit a Data Use Certification to an appropriate NIH Data Access Committee for approval.
Started Jul 2020 (actual). Primary completion is estimated for Jun 2027, 83 months after the start.
Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 83 months is above that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.